Market Trends Rezolute receives breakthrough therapy designation for treatment of hypoglycemiaBy admin8996erT0allJanuary 7, 2025 Rezolute (NASDAQ:RZLT) rose 6% after it announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to…
Market Trends Stoke Therapeutics to initiate late-stage study for the treatment of Dravet syndromeBy admin8996erT0allJanuary 7, 2025 designer491/iStock via Getty Images Stoke Therapeutics (NASDAQ:STOK) announced alignment with global regulatory agencies on the design of the company’s Phase…
Market Trends PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinoneBy admin8996erT0allDecember 19, 2024 Shidlovski PTC Therapeutics (NASDAQ:PTCT) has submitted a New Drug Application to the U.S. FDA seeking approval of its Friedreich ataxia…
